NCT02855918

Blood Biomarkers in Suicidal Behaviour

Modification of the Expression of ADARs and PDE8A Editing in Suicidal Behavior

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 600 (actual)
• Sponsor: University Hospital, Montpellier · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Suicidal behavior (SB) is a major public health problem in France, with more than 10,000 suicides and 220,000 suicide attempts per year. According to the commonly accepted model for understanding suicidal behavior, individuals who carry a suicidal act when subjected to stress factors (environmental stress, depression, substance ...) are those which have a specific vulnerability. These vulnerabilities can be considered as clinical parameters (propensity to despair, aggressive and/or impulsive traits), neurobiological parameters (dysfunction of the serotonergic system, ...) and cognitive parameters (taking disadvantageous decision ...). Suicidal vulnerability is partly underpinned by genetic factors. The interest of current researches is to identify biomarkers that will improve the opportunities for early identification of subject with a risk for SB. Numerous scientific studies, including post-mortem studies of the brains of suicide completers, have established a link between dysregulation of the ribonucleic acids editing (RNA) of certain genes, the enzymatic activity of Adenosine deaminases acting on RNA (ADARS) responsible for this edition and suicidal behavior. A prospective study is needed to quantify and qualify in the blood of depressed patients (with or without a history of suicide) and healthy controls, the editing changes and the expression and alteration of the activity of ADARS.

Detailed description

Over two years, 600 participants will be recruited: * 225 subjects with current major depressive episode and an history of suicide attempt (depressed suicide attempters) * 225 subjects with current major depressive episode but with no personal history of suicide attempt (affective controls) * 150 subjects with no history of psychopathology whole life (healthy controls) Each patient will attend a total of 3visits during a follow-up period of 6 months +/- 15 days (inclusion, visit at 3 and 6 months).

Conditions

• Major Depression

Interventions

Type	Name	Description
OTHER	Blood sample for genetic purpose	All the participants will performed the same evaluations and blood analysis : * A clinical assessment by psychiatrist * Self report questionnaires for the assessment of a potential mood disorder and history of SB, moral/physical pain, personality traits… * A neuropsychological assessment for the evaluations of cognitive performances * A routine blood sampling to the realization of a standard blood test * A specific blood sampling (PAXgene® tubes) to extract total RNA of blood cells and measure the expression of ADARS RNA and editing of the PDE8A transcript.

Timeline

• Start date: 2016-09-23
• Primary completion: 2020-06-24
• Completion: 2020-06-24
• First posted: 2016-08-04
• Last updated: 2021-12-27

Locations

1 site across 1 country: France